

# Joint Meeting SFI & DGfI

26-29  
SEPTEMBER 2023

Palais de la Musique et des Congrès  
STRASBOURG



P111

## SMAD4 TGF- $\beta$ -independent function dictates naïve CD8<sup>+</sup> T cell fate and prevents gut inflammation

IGALOUZENE R. <sup>1</sup>, HERNANDEZ-VARGAS H. <sup>1</sup>, GUYENNON A. <sup>1</sup>, BENECH N. <sup>1</sup>, BAUCHD. <sup>1</sup>, BARRACHINA C. <sup>1</sup>, DUBOIS E. <sup>1</sup>, MARIE J. <sup>1</sup>, SOUDJA S.

<sup>1</sup>

<sup>1</sup> Centre de Recherche en cancérologie de Lyon, Lyon, France

Characterizing naïve T cells as being completely "naïve" may not accurately reflect their true nature and functionality. SMAD4, a key mediator of TGF- $\beta$  signaling, plays a crucial role in T cells preventing chronic intestinal inflammation. In spite of this, the mechanisms underlying this control remain obscure. Using different genetic and epigenetic approaches, we reveal that SMAD4 in naïve CD8 T cells prevents microbiota-mediated chronic intestinal inflammation in a TGF- $\beta$ -independent manner by preconditioning their fate prior to their activation. Mechanistically, SMAD4 acts as a basal repressor of TGF- $\beta$ -target genes by histone deacetylations in naïve CD8 T cells. Inversely to TGF- $\beta$  signaling, SMAD4 endows naïve CD8 T cells with a robust effector program and limits their potential differentiation into gut intraepithelial lymphocytes. In addition, in a feedforward mechanism, SMAD4 inhibits the expression of TGF- $\beta$ -signaling-repressors, predisposing CD8 T cells to an efficient TGF- $\beta$  mediated immunosuppression. Hence, in a TGF- $\beta$ -independent manner, SMAD4 both blocks the TGF- $\beta$  signature in naïve CD8 T cells and restrains their future epithelial localization and intestinal pathology. Our findings unveil SMAD4 as a critical regulator of CD8 T cell differentiation, programming the fate of CD8 T cells during their naïve stage, ultimately shaping their behavior and function in subsequent immune responses. These insights provide an original avenue for modulating future immune responses.